Two-Drug Combo Superior to Sunitinib as First-Line Therapy for Advanced RCC
Compared with sunitinib alone, nivolumab plus cabozantinib therapy was associated with a 49% decreased risk for progression and 40% decreased risk for death.
Kidney Cancer
Investigators ID Predictors of CKD Progression After Radical Nephrectomy
Kidney microstructural features appear predictive of progressive CKD and mortality following radical nephrectomy.
Immunotherapy Improves Survival Despite Brain Metastases
Immunotherapy improved median overall survival by 7.5 months regardless of what other treatments patients received.
Metastatic Renal Cell Carcinoma: Metastasectomy Improves Outcomes
There is evidence to support the role of metastasectomy in providing patients with mRCC an improvement in certain clinical outcomes.
Metastasectomy Survival Benefit in mRCC Cases Confirmed
New data show that complete metastasectomy for selected cases of metastatic renal cell carcinoma (mRCC) prolongs survival in the postcytokine therapy era.
PN Risks May Outweigh Benefits in Some CKD Cases
Investigators highlight the importance of preoperative renal biopsy to rule out an indolent or benign tumor in patients with stage 4 CKD.
Renal Cell Carcinoma Outcomes: Does Hemodialysis Make a Difference?
Hemodialysis was found to be a poor prognostic factor for patients with RCC.
Complete Metastasectomy Found to Prolong Survival in mRCC
A study showed that mortality risk was reduced by 59% for patients who underwent complete metastasectomy compared with those who did not.
Growth Rates of Small RCC Tumors Vary by Histologic Subtype
Clear cell renal cell carcinoma tumors grow at a faster rate than papillary type 1 tumors, according to a new study.
Plasma DNA Assay Accurately Identifies Renal Cell Carcinoma
An assay that measures tumor-derived cell-free DNA in plasma discriminated between patients with and without renal cell carcinoma with 99% accuracy.
-
Loading...
-
Loading...
Next post in Kidney Cancer
